|Bid||0.56 x 100|
|Ask||0.56 x 200|
|Day's Range||0.55 - 0.57|
|52 Week Range||0.16 - 4.75|
|PE Ratio (TTM)||-0.43|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
On a per-share basis, the San Ramon, California-based company said it had a loss of 45 cents. Losses, adjusted to account for discontinued operations, came to 9 cents per share. In the final minutes of ...
SAN RAMON, Calif., May 10, 2017-- Galena Biopharma, Inc., a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial results ...